Sword Health will acquire Headspace, effective 14 September, according to public documents. The deal represents one of the most significant digital health acquisitions in the behavioral health space. New York-based Sword Health started in musculoskeletal care but has expanded into women's health, cardiometabolic care, and mental health. San Francisco-based Headspace offers therapy, coaching, wellness apps, and EAP services. Both companies focus on business-to-business contracting with employers and health plans. The documents state clinical services will not be reduced, though corporate staff reductions may occur where functions overlap. Sword Health has raised an estimated $495 million, whilst Headspace has raised approximately $321 million, according to Crunchbase. Headspace was valued at $3 billion following its 2021 merger with Ginger Health.

2026 healthcare forecast cloudy, but AI rays could poke through. Venrock's 10th annual survey of healthcare insiders reveals they're a pessimistic bunch lately, harboring cynicism about recent policy developments and the future of health tech IPOs, though views on AI were more of a mixed bag. Let's break down the results. But first, a bit about the survey. More than 200 leaders from all corners of healthcare shared their thoughts with Venrock. Some areas were better represented than others. * Respondents skewed toward the private sector (28%), investing (20%), life sciences or pharma (16%), professional services (8%), and academia (7%). Venrock loaded up the questionnaire with AI inquiries. Big picture: Insiders are becoming more comfortable with the tech, but remain mindful of its downsides. * Trust in AI grew for 73% and fell for 2% (unclear who hurt them). * Just 9% view AI as the most overrated trend in healthcare. * HIPAA breaches (24%), harmful hallucinations (19%), and overspending on healthcare-specific platforms (28%) ranked highest among possible AI pitfalls. * Most expect AI to create an costly arms race between payers and providers (63%) as each side rolls out bots specifically designed to argue with other bots. Here's another fun one: M&A targets. There's no consensus on who will get snapped up next, but the industry seems confident it will be a big name in AI-powered services. * OpenEvidence (21%), Komodo Health (18%), Abridge (14%), and Sword Health (11%) were the top answers out of 10 companies, but only after none of the above (46%). So the hottest firms are going public? Nope - that's one thing people can agree on. * Only 3% think health tech IPOs will be back in style this year, with the rest split roughly down the middle between 2027 and 2028 or beyond. * For those keeping score, 42% of last year's respondents predicted a health tech firm would go public in the first half of 2026. Tumbleweeds... In fairness, it's hard to predict the future, especially with $1.15T in Medicaid cuts looming over everyone's heads. * Will they harm rural hospitals? Empty state coffers? Ruin MCOs? Strain blue-state safety net hospitals? Most checked all of the above (65%). The Takeaway Some of the smartest folks in healthcare think we're heading toward a world of payer-provider bot wars, sluggish health tech IPOs, and brutal fallout from Medicaid cuts. Here's to hoping Venrock's survey missed the mark.

Trialbee appoints Michael Meerovich as Chief Financial Officer to accelerate global growth strategy. Seasoned finance executive brings two decades of experience scaling software and healthcare technology businesses to support Trialbee's next phase of high-growth, AI-driven innovation. Trialbee, the global leader in technology-driven patient recruitment, has appointed Michael Meerovich as Chief Financial Officer. Based in New York, Meerovich will play a central role in shaping the company's financial strategy, supporting value creation initiatives, and building the financial foundation required to support Trialbee's expanding global footprint. With AI and new technologies reshaping patient recruitment, Trialbee continues to innovate with its Honey Platform(TM), scale its team, and expand global delivery capabilities to meet rising demand from top biopharma sponsors running many of the industry's largest clinical programs. The opportunities ahead have never been greater - and Meerovich's leadership will be instrumental in helping Trialbee capture additional market opportunities following a strategic investment from Varsity Healthcare Partners and five consecutive years of significant growth. "I'm always drawn to companies focused on making a positive impact on society, and this industry doesn't get the attention it deserves," said Meerovich. "Patient recruitment is an incredibly fragmented, complex, and manual part of the drug development process that often drives significant delays and cost overruns in clinical trials. Trialbee possesses both the technology and the world-class team to help solve that massive problem. This company offers a unique opportunity to make a real impact on millions of patients' lives, and I'm excited to support that mission." "Michael is the strategic, forward-looking CFO Trialbee needs for our next phase of growth," said Matt Walz, CEO of Trialbee. "Our pace of innovation is multiplying while our customers, partnerships and offerings are expanding quickly, evidenced by the new AI capabilities we've been releasing with our Honey Platform(TM). It is important we maintain our focus on our sponsors, CROs, sites, partners, and the patients we ultimately serve while growing the underlying business. Michael's strategic counsel and financial expertise will bring a step change in how we scale as a business while executing our strategic priorities and managing our growth. He's going to be an exceptional partner to the team and a great cultural fit." Meerovich joins Trialbee from Mobile Health, a digital health and wellness platform, where he served as Chief Financial Officer. He brings 20 years of experience building and scaling finance organizations across software and technology-enabled businesses, most recently at the intersection of healthcare and technology. Meerovich previously held senior financial leadership roles at Sword Health and Collibra, where he helped drive rapid growth while scaling finance and operations. Meerovich holds an MBA in Finance and Strategy from New York University's Stern School of Business and a B.S. in Finance from Penn State University. [To share your insights with us, please write to [email protected]]